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Purpose: Locally recurrent non-small cell lung cancer (LR-NSCLC) remains challenging
to treat, particularly in patients having received prior radiotherapy. Heterogeneous pop-
ulations and varied treatment intent in existing literature result in significant limitations
in evaluating efficacy of lung re-irradiation. In order to better establish the impact of
re-irradiation in patients with LR-NSCLC following high-dose radiotherapy, we report
outcomes for patients treated with prior sublobar resection and brachytherapy that
subsequently underwent stereotactic body radiotherapy (SBRT).
Methods: A retrospective review of patients initially treated with sublobar resection and
I125 vicryl mesh brachytherapy, who later developed LR-NSCLC along the suture line, was
performed. Patients received salvage SBRT with curative intent. Dose and fractionation
were based on tumor location and size, with a median prescription dose of 48Gy in 4
fractions (range 20–60Gy in 1–4 fractions).
Results: Thirteen consecutive patients were identified with median follow-up of 2.1 years
(range 0.7–5.6 years). Two in-field local failures occurred at 7.5 and 11.1months, resulting
in 2-year local control of 83.9% (95% CI, 63.5–100.0%). Two-year disease-free survival
and overall survival estimates were 38.5% (95% CI, 0.0–65.0%) and 65.8% (95% CI,
38.2–93.4%). Four patients (31%) remained disease-free at last follow-up. All but one
patient who experienced disease recurrence developed isolated or synchronous distant
metastases. Only one patient (7.7%) developed grade 3 toxicity, consisting of grade
3 esophageal stricture following a centrally located recurrence previously treated with
radiofrequency ablation.
Conclusion: Despite high-local radiation doses delivered to lung parenchyma previously
with I125 brachytherapy, re-irradiation with SBRT for LR-NSCLC results in excellent
local control with limited morbidity, allowing for potential disease cure in a subset of
patients.
Keywords: SBRT, radiosurgery, re-irradiation, lung cancer, brachytherapy, non-small cell lung cancer, recurrent
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Introduction
Improved access to computed tomography (CT) and adoption of
screening with low-dose CT, which has been proven to reduce
lung cancer mortality, has led to greater detection of earlier
stage lung cancers in a high-risk population (1, 2). Despite this
improvement in screening, approximately 25% of patients with
early stage non-small cell lung cancer (NSCLC) have poor pul-
monary function, limiting their ability to tolerate lobectomy (3).
To avoid the survival detriment seen with untreated NSCLC,
potentially curative alternatives for this medically high-risk pop-
ulation include stereotactic body radiotherapy (SBRT), hypofrac-
tionated conventional radiotherapy, radiofrequency ablation, and
sublobar resection (4–8).Historical data suggested sublobar resec-
tion resulted in inferior local control as compared to lobectomy,
leading to integration of I125 vicryl mesh brachytherapy to reduce
this risk (9, 10).
Recently published results from a randomized trial demon-
strate a low rate of local relapse altogether, resulting in no demon-
strated benefit to vicryl mesh brachytherapy following sublobar
resection (11). Nonetheless, local relapse for patients treated with
prior brachytherapy or high-dose radiotherapy such as SBRT has
limited salvage options following locally recurrent disease due to
concerns of toxicity with lung re-irradiation coupled with poor
pulmonary reserve. Without effective salvage therapy, locore-
gional recurrence often results in death (12, 13). Re-irradiation
with SBRT or EBRT has been previously evaluated with varying
results regarding both toxicity and clinical outcomes (14–22).
No published data exist regarding treatment of patients fol-
lowing vicryl mesh brachytherapy, where greater concern for
necrosis and pneumonitis theoretically may exist due to high-
local doses. Here, we report outcomes and toxicities from a sub-
set of patients with locally recurrent NSCLC following sublobar
resection and I125 vicryl mesh brachytherapy treated with salvage
SBRT.
Materials and Methods
Following Institutional Review Board approval, a retrospective
reviewwas conducted for patients with NSCLC treated with SBRT
at the University of Pittsburgh Cancer Institute. Patients included
previously received sublobar resection with I125 vicryl mesh
brachytherapy for a primary NSCLC, later developing local recur-
rence adjacent to the brachytherapy mesh. All patients received
re-irradiation using SBRT with varying fractionation regimens,
based on the proximity of critical structures and at discretion of
the treating physician. Re-irradiation was defined by the relation
of the planning target volume (PTV) to the vicryl mesh, such that
the PTV was within 1 cm from the mesh.
At the time of recurrence, patients underwent either CT
or 18F-fluorodeoxyglucose (18F-FDG) positron emission tomog-
raphy/CT (PET/CT) for re-staging and/or radiation treatment
planning. Patients with biopsy-confirmed or radiographic nodal
or distant metastases were excluded. Determination of recur-
rent NSCLC was either histologically proven or radiographically
defined based on morphology and/or serial imaging.
Patients received SBRT through various platforms:
CyberKnife™ (Accuray, Inc., Sunnyvale, CA, USA), Trilogy™
(Varian Medical Systems, Palo Alto, CA, USA), or TrueBeam™
(Varian Medical Systems). Treatment simulation consisted
of a four-dimensional high-resolution CT scan (4DCT) with
intravenous contrast if medically feasible. A custom BodyFIX™
vacuum bag (Elekta AB, Stockholm, Sweden) was used for
immobilization. Respiratory gating was then utilized for
TrueBeam™ or Trilogy™ treatment based on tumor motion,
with a cut-off of >5mm in any dimension on raw phase images
to indicate the need for gating. The Synchrony™ Respiratory
Tracking System (Accuray, Inc.) was utilized for real-time
tracking with CyberKnife™, in conjunction with pre-placed
fiducials.
Treatment planning in either MultiPLAN™ (Accuray, Inc.) or
Eclipse (Varian Medical Systems) was completed, identifying the
gross tumor volume (GTV) on end-exhalation or free breathing
CT simulation scans based on the need for gating. Tumors treated
on the CyberKnife™ platform had PTV expansions of 1 cm in
the craniocaudal direction and 0.5 cm radially similar to that
in Radiation Therapy Oncology Group (RTOG) 0236 (4). For
TrueBeam™ or Trilogy™ treatment, a minimum expansion of
5mm was added for a PTV, incorporating an additional margin
for tumor motion assessed on 4DCT. Typically, an incorporated
internal target volume (ITV) involved adding the extent ofmotion
within the gated window to the minimum PTV margin in the
direction of movement (23). Given variations in fractionation
regimens, dosimetric constraints varied although at least 95% of
the PTV was expected to be covered by the prescription dose.
Treatment was delivered every other day.
Follow-up imaging consisted of CT or PET/CT at intervals
based on physician discretion, initially starting 8–12weeks from
completion of SBRT. Criteria for local failure were based on the
RTOG 0236 definition: 20% increase in greatest dimension per
CT and evidence of tumor viability via FDG-avidity or histologic
confirmation (4). Regional failure included hilar, mediastinal,
and/or supraclavicular nodal failure. All other failures, including
the contralateral lung, were coded as distant metastases unless a
new solitary lung lesion was present, suggestive of a new primary
lung cancer. Common Terminology Criteria for Adverse Events
(version 4.03) was used to record toxicity.
Statistical analysis was conducted using SPSS version 22 (IBM
Corp., Armonk, NY, USA). Kaplan–Meier methods were used
to assess local control, distant-metastasis free survival, disease-
free survival, and overall survival. Log-rank test was conducted
to assess factors associated with the various treatment outcomes.
Biological effective doses (BEDs) were calculated using the linear-
quadratic equation with an α/β value of 10 for tumor. For descrip-
tive purposes, BED values were converted to equivalent dose at
2Gy (EQD2) when discussing toxicity.
Results
Thirteen patients were identified with recurrent NSCLC along
the brachytherapy mesh, of which nine patients (69%) had
histologic confirmation (Table 1). Recurrence occurred at a
median of 3.8 years from initial diagnosis (range 0.9–9.5 years).
Despite a median age of 71 years, the median Karnofsky perfor-
mance status score was 90% (range 60–100%). The right upper
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TABLE 1 | Patient and disease-related characteristics at the time of
stereotactic body re-irradiation.
Value
Age, median (range) 71 years (54–87 years)




History of tobacco smoking (n, %)
Yes 13 (100%)
No 0 (0%)





Prior therapy following recurrence (n, %)
Radiofrequency ablation 3 (23%)
None 10 (77%)
Histology (n, %)
Squamous cell carcinoma 5 (38.5%)
Adenocarcinoma 7 (53.5%)
Non-small cell carcinoma, NOS 1 (8%)
Time to recurrence, median (range) 3.8 years (0.9–9.5 years)
Diagnostic criteria for recurrence (n,%)
Biopsy-proven 9 (69%)
Clinical/radiographic 4 (31%)
Location (lobe) of recurrence (n, %)
Right upper lobe 5 (38%)
Right middle lobe 0 (0%)
Right lower lobe 3 (23%)
Left upper lobe 4 (31%)
Left lower lobe 1 (8%)
Location of recurrence (n, %)
Central 4 (31%)
Peripheral 9 (69%)
KPS, Karnofsky performance status; AJCC, American Joint Committee on Cancer; NOS,
not otherwise specified.
(38%) and left upper (31%) lobes were the most common loca-
tions, with most recurrences located >2 cm from the central
bronchial tree (69%). Patients were treated using either True-
Beam/Trilogy (46%) or CyberKnife (54%). The most common
fractionation schemes were 48Gy in 4 fractions (46%) or 60Gy
in 3 fractions (38%), resulting in a median BED10 of 105.6Gy
(Table 2).
Clinical outcomes are indicated in Table 3. With a median
follow-up time of 2.1 years (range 0.7–5.6 years), two patients
(15.4%) developed local failure, one with isolated local failure and
the other patient with simultaneous local, regional, and distant
failure. Both local recurrences occurred within the planning tar-
get volumes at 7.5 and 11.1months after receiving a BED10 of
85.5 and 180.0Gy, respectively. Re-irradiation planning treatment
volumes for these two patients were 16.6 and 25.3 cc. The 2-
year Kaplan–Meier estimated local control rate was 83.9% (95%
CI, 63.5–100.0%; Figure 1). No factors were found to be associ-
ated with local control, including PTV volume, BED10, time to
recurrence or tumor location.
Four patients (31%) remain disease-free at last follow-up; three
patients (23%) are both alive and disease-free. Crude rates of dis-
ease recurrence were as follows: isolated local (n= 1, 7.7%); syn-
chronous local, regional, and distant (n= 1, 7.7%); synchronous
regional and distant (n= 2, 15.4%); and isolated distant (n= 5,
38.5%). Two-year estimates for disease-free survival and overall
survival were 38.5% (95% CI, 0.0–65.0%) and 65.8% (95% CI,
38.2–93.4%), respectively (Figure 2). Median overall survival was
26.4months.
No patients developed grade 3 or greater pulmonary toxicity,
including lung fibrosis and pneumonitis. However, two patients
(15.4%) did develop grade 2 fibrosis and grade 2 dyspnea at 9.4 and
10.1months after treatment. No grade 2 esophageal toxicities were
seen. One patient (7.7%) developed a grade 3 esophageal stricture
at 3.1months after treatment requiring endoscopic dilatation. Of
particular note, this patient had a central tumor recurrence treated
with radiofrequency ablation prior to SBRT. Given proximity
to central structures, the patient received 45Gy in 5 fractions,
although the maximal point dose to the esophagus was 38.8Gy
(7.8Gy/fraction), resulting in an EQD2 of 83.8Gy.
Discussion
Management of locally recurrent non-small cell lung cancer
(LR-NSCLC) remains challenging due to limitations from prior
therapy and presence of medical comorbidities that often pre-
clude aggressive therapy. For this reason, less invasive therapies
with limited risk of morbidity are often ideal. Stereotactic body
radiotherapy provides such benefits and enables the ability to
deliver conformal and high doses to tumors. However, for patients
who received prior high-dose radiotherapy, concern always exists
regarding added toxicity from re-irradiation. Results presented
here suggest that even with previous high-local doses to normal
lung from brachytherapy, salvage SBRT resulted in limited toxicity
and provided an efficacious salvage option for locally recurrent
lung cancer. Specifically, the 2-year local control rate remained
high at 83.9% with a median survival of 26.4months.
Clinical outcomes following re-irradiation of LR-NSCLCs have
been difficult to interpret due to heterogeneous populations and
loose definitions of re-irradiation. For example, among 11 studies
reviewed by Jeremic et al., only 3 trials delivered external beam
re-irradiation using curative doses (median dose 50Gy) (15).
Nonetheless, local control remains limited with external beam
re-irradiation, ranging from 16.7 to 42.0% in these trials (14,
24, 25). In a recently published larger cohort of 102 patients,
McAvoy et al. identified 41 patients with locoregional recurrence
within the prior radiotherapy field, among which 46% local con-
trol was achieved after re-irradiation using various modalities
(26). Although many of these series included more advanced
lung cancer at recurrence, re-irradiation with conventional frac-
tionation appears to result in, at best, modest rates of local
control.
Several publications have addressed feasibility and toxicity
using SBRT re-irradiation for lung tumors. Many of these series
are limited again by mixed treatment intent, varying definitions
of re-irradiation and diverse histology and disease stage (16, 17,
19–22). Adequate estimation of long-term clinical outcomes for
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TABLE 2 | Stereotactic body radiotherapy (SBRT) re-irradiation characteristics.
All patients (n= 13) TrueBeam/Trilogy (n=6) CyberKnife (n=7)
PTV volume
Median (range) 25.3 cc (10.8–107.8 cc) 26.8 cc (10.8–107.8 cc) 25.3 cc (14.7–52.6 cc)
Number of non-zero beams/fields
Median (range) – 11 (10–12) 154 (137–162)
Dose-fractionation schedule (n, %)
9Gy5 fractions 1 (8%) 1 (17%) 0 (0%)
12Gy4 fractions 6 (46%) 3 (50%) 3 (43%)
20Gy3 fractions 5 (38%) 2 (33%) 3 (43%)
20Gy1 fraction 1 (8%) 0 (0%) 1 (14%)
Re-irradiation BED10
Median (range) 105.6Gy (60.0–180.0Gy) 105.6Gy (85.5–180.0Gy) 105.6Gy (60.0–180.0Gy)
Prescription isodose line
Median (range) 80% (80–90%) 86% (82–90%) 80% (80–80%)
Minimum PTV dose, relative to prescription dose
Median (range) 83% (50–100%) 89% (75–100%) 66% (50–90%)
Heterogeneity index
Median (range) 1.23 (1.10–1.25) 1.15 (1.10–1.22) 1.25 (1.23–1.25)
Median R50%
All PTVs 3.9 5.2 3.0
PTV <20 cc 4.3 4.8 3.8
PTV 20–50 cc 3.0 5.5 2.4
PTV >50 cc 4.7 6.4 2.9
Treatment time
Median (range) 13 days (1–16days) 12.5 days (5–16 days) 9 days (1–13days)
SBRT, stereotactic body radiotherapy; PTV, planning target volume; BED, biological effective dose; R50%, ratio of 50% prescription isodose volume to the PTV.












1 5.2 Y Peripheral 60.0 0.7 N DF Y
2 1.6 Y Peripheral 105.6 1.7 N DF Y
3 7.3 Y Peripheral 180.0 2.2 N RF+DF Y
4 1.3 N Peripheral 180.0 1.1 N LF+RF+DF Y
5 3.8 N Peripheral 180.0 2.1 N DF Y
6 0.9 Y Central 105.6 5.6 Y – N
7 7.6 Y Peripheral 105.6 2.5 Y – Y
8 2.6 N Peripheral 180.0 2.7 Y – N
9 2.2 Y Peripheral 105.6 1.6 N RF+DF Y
10 4.3 Y Central 105.6 3.8 N DF N
11 9.5 Y Central 180.0 3.1 Y – N
12 2.9 N Central 85.5 1.5 N LF N
13 6.9 Y Peripheral 105.6 1.5 N DF N
ID, patient number; BED, biologically equivalent dose; LF, local failure; RF, regional failure; DF, distant failure.
patients with LR-NSCLC alone within the prior radiotherapy field
is therefore difficult to determine. Only two of these studies either
reported separate outcomes or included only LR-NSCLC with
SBRT re-irradiation defined as overlap with the prior treatment
field (17, 19). Hearn et al. reported 10 patients treated with salvage
SBRT, resulting in crude local control and overall survival rates
of 60 and 30% (17). Parks et al. identified 29 patients treated
with repeat SBRT, where 13 patients underwent re-irradiation
of in-field recurrences leading to a 2-year locoregional relapse-
free survival rate of 58% (19). These two studies suggest that
despite a high-equivalent dose delivered using SBRT, locoregional
control appears only slightly improved, if not comparable, to
other radiotherapy methods. Conversely, in the present study, 2-
year local control remained excellent at 83.9%. Such a finding
may reflect rigorously selected patients, where many underwent
PET/CT re-staging with identification of isolated local disease.
Other explanations include comparably long re-treatment inter-
vals (median time to re-irradiation 3.8 years), which may attest
to disease biology and initial disease stage. Multivariate analysis
of the prior study by McAvoy et al. illustrated improved local
control and survival with a re-treatment interval >6months and
lower initial T stage (26). Lastly, in patients with prior brachyther-
apy, cell-kill mechanisms may be different from that delivered
through SBRT. Thus, patients treated with prior brachytherapy
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FIGURE 1 | Kaplan–Meier estimate of local control.
FIGURE 2 | Kaplan–Meier estimates of disease-free (A) and overall (B) survival.
may be responsive to re-irradiation using high doses per fraction
(i.e., SBRT). Nonetheless, these findings, among a much more
homogenous population, should indicate that in properly selected
patients, re-irradiation with SBRT for locally recurrent NSCLC
can provide improved local control in a shorter treatment course.
Re-irradiation, particularly using high-dose regimens such as
that seen with SBRT, comes with added concerns of toxicity. In
re-irradiation series using external beam radiotherapy, rates of
grade 3 or greater pneumonitis and esophagitis range from 5 to
21 and 4 to 6%, respectively (15). Here, we reported selectively on
patientswith recurrence near brachytherapymesh to illustrate that
despite prior high-radiation doses, severe pulmonary toxicity rates
remain exceedingly low in a carefully planned and well-executed
schema of stereotactic radiotherapy, a more conformal technique.
Lung parenchyma functions as a parallel organ and thus volume
of functional lung irradiated plays a larger factor than maximum
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point dose. Such findings have been confirmed using external
beam radiotherapy, showing that volume of lung irradiated, even
at low doses, correlates with risk of pneumonitis and atelecta-
sis (27–30). Similar dose–volume parameters have been estab-
lished for stereotactic body radiotherapy (31, 32). Utilizing SBRT
for re-irradiation of lung lesions limits the volume of normal
lung receiving dose greater than that seen with conventional
methods, resulting in low rates of severe pneumonitis as con-
firmed here.
In the setting of SBRT re-irradiation for lung tumors, tumor
volume and central structure tolerance should have a greater
impact on management decisions as opposed to concerns over
high-local doses to lung parenchyma. In our study, we identi-
fied one patient who developed late grade 3 esophagitis after
receiving adjacent radiofrequency ablation and a maximal point
dose of 38.8Gy (EQD2 83.8Gy). Studies using external beam
radiotherapy for re-irradiation have shown low rates of grade 3
esophagitis (4–6%), although this may be a function of tumor
location (15). High doses with SBRT may be less forgiving to
central mediastinal structures, as evidenced in both prospective
and retrospective series (16, 21, 33). In the setting of re-irradiation,
Peulen et al. noted all grade 4–5 toxicities occurred in centrally
located lesions (16). Three patients developed grade 5 complica-
tions due to hemorrhage. Kilburn et al. noted one patient death
due to development of an aortoesophageal fistula (21). Thus, the
approach of re-irradiation using SBRT should be taken cautiously
for centrally located lesions.
Our study, like many others evaluating re-irradiation, is limited
by both the retrospective nature of review and small sample size.
We intentionally identified a select population in order to provide
a clear analysis of a comparable patient cohort as opposed to
that done in a number of re-irradiation studies. Although varying
fractionation regimens make direct interpretation challenging, a
majority received more commonly utilized regimens (48Gy in 4
fractions or 60Gy in 3 fractions). Additionally, with a median
follow-up time of 2.1 years, whether these favorable local control
rates would persist over time remains unknown. Despite these
limitations, these results should provide re-assurance that in prop-
erly selected patients with locally recurrent NSCLC, even in heav-
ily irradiated regions, stereotactic body radiotherapy can provide
excellent local control with limited morbidity, resulting in cure
among a small subset of patients. In the future, better tolerated
and/or targeted systemic therapy may aid in decreasing the high
rate of distant metastases in this population, which remained the
predominant mode of failure.
Conclusion
Stereotactic body radiotherapy for locally recurrent NSCLC fol-
lowing prior radiotherapy is an effective salvage therapy with
limited morbidity, even despite high doses of prior radiotherapy
with I125 vicryl mesh brachytherapy. Severe pulmonary parenchy-
mal toxicity remains low with re-irradiation using SBRT, likely
related to limited dose to large lung volumes. Centrally located
tumors should be cautiously selected for re-irradiation using
SBRT. Although a proportion of patients may achieve cure, for
most patients, optimization of systemic therapy is critical to offset
the risk of distant metastases.
References
1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg
CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-
dose computed tomographic screening. N Engl J Med (2011) 365(5):395–409.
doi:10.1056/NEJMoa1102873
2. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT
screening for lung cancer brings forward early disease. The randomised Danish
lung cancer screening trial: status after five annual screening rounds with low-
dose CT. Thorax (2012) 67(4):296–301. doi:10.1136/thoraxjnl-2011-200736
3. Mentzer SJ, Swanson SJ. Treatment of patients with lung cancer and severe
emphysema. Chest (1999) 116(6 Suppl):477S–9S. doi:10.1378/chest.116.suppl_
3.477S
4. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al.
Stereotactic body radiation therapy for inoperable early stage lung cancer.
JAMA (2010) 303(11):1070–6. doi:10.1001/jama.2010.261
5. Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L, et al. Accelerated
hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-
term results. Int J Radiat Oncol Biol Phys (2011) 79(2):459–65. doi:10.1016/j.
ijrobp.2009.11.003
6. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, et al. Response
to radiofrequency ablation of pulmonary tumours: a prospective, intention-
to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol (2008)
9(7):621–8. doi:10.1016/S1470-2045(08)70155-4
7. Pennathur A, Luketich JD, Abbas G, Chen M, Fernando HC, Gooding WE,
et al. Radiofrequency ablation for the treatment of stage I non-small cell lung
cancer in high-risk patients. J Thorac Cardiovasc Surg (2007) 134(4):857–64.
doi:10.1016/j.jtcvs.2007.04.060
8. Landreneau RJ, Normolle DP, Christie NA, Awais O, Wizorek JJ, Abbas G,
et al. Recurrence and survival outcomes after anatomic segmentectomy versus
lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched
analysis. J Clin Oncol (2014) 32(23):2449–55. doi:10.1200/JCO.2013.50.8762
9. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited
resection for T1 N0 non-small cell lung cancer. Lung cancer study group. Ann
Thorac Surg (1995) 60(3):615–22. doi:10.1016/0003-4975(95)00537-U
10. Fernando HC, Santos RS, Benfield JR, Grannis FW, Keenan RJ, Luketich
JD, et al. Lobar and sublobar resection with and without brachytherapy for
small stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg (2005)
129(2):261–7. doi:10.1016/j.jtcvs.2004.09.025
11. Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron
DE, et al. Impact of brachytherapy on local recurrence rates after sublobar
resection: results from ACOSOG Z4032 (Alliance), a phase III randomized
trial for high-risk operable non-small-cell lung cancer. J Clin Oncol (2014)
32(23):2456–62. doi:10.1200/JCO.2013.53.4115
12. Hung JJ, Hsu WH, Hsieh CC, Huang BS, Huang MH, Liu JS, et al.
Post-recurrence survival in completely resected stage I non-small cell lung
cancer with local recurrence. Thorax (2009) 64:192–6. doi:10.1136/thx.2007.
094912
13. Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site Group
of Cancer Care Ontario’s Program in Evidence-based Care. Second-line or
subsequent systemic therapy for recurrent or progressive non-small cell lung
cancer: a systematic review and practice guideline. J Thorac Oncol (2006)
1:1042–58. doi:10.1097/01243894-200611000-00021
14. Okamoto Y, Murakami M, Yoden E, Sasaki R, Okuno Y, Nakajima T, et al.
Reirradiation for locally recurrent lung cancer previously treated with radi-
ation therapy. Int J Radiat Oncol Biol Phys (2002) 52(2):390–6. doi:10.1016/
S0360-3016(01)02644-X
15. Jeremic B, Videtic GM. Chest reirradiation with external beam radiotherapy for
locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol
Phys (2011) 80(4):969–77. doi:10.1016/j.ijrobp.2011.01.069
16. Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, et al.
Toxicity after reirradiation of pulmonary tumours with stereotactic body
radiotherapy. Radiother Oncol (2011) 101(2):260–6. doi:10.1016/j.radonc.2011.
09.012
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 1096
Gill et al. Salvage SBRT for recurrent NSCLC after brachytherapy
17. Hearn JW, Videtic GM, Djemil T, Stephans KL. Salvage stereotactic body
radiation therapy (SBRT) for local failure after primary lung SBRT. Int J Radiat
Oncol Biol Phys (2014) 90(2):402–6. doi:10.1016/j.ijrobp.2014.05.048
18. Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW Jr, et al. Stereotactic
ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac
Oncol (2012) 7(9):1462–5. doi:10.1097/JTO.0b013e31825f22ce
19. Parks J, Kloecker G, Woo S, Dunlap NE. Stereotactic body radiation therapy as
salvage for intrathoracic recurrence in patientswith previously irradiated locally
advanced non-small cell lung cancer.Am JClinOncol (2014). doi:10.1097/COC.
0000000000000039
20. Seung SK, Solhjem M. Salvage SBRT for previously irradiated lung cancer.
J Cancer Ther (2011) 2:190–5. doi:10.4236/jct.2011.22024
21. Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson
WH, et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT)
techniques as first or second course of treatment. Radiother Oncol (2014)
110:505–10. doi:10.1016/j.radonc.2013.11.017
22. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, et al. Stereotactic
body radiation therapy for patients with lung cancer previously treated with
thoracic radiation. Int J Radiat Oncol Biol Phys (2010) 78(5):1387–93. doi:10.
1016/j.ijrobp.2009.09.070
23. Zhao B, Yang Y, Li T, Li X, Heron DE, HuqMS. Image-guided respiratory-gated
lung stereotactic body radiotherapy: which target definition is optimal? Med
Phys (2009) 36(6):2248–57. doi:10.1118/1.3129161
24. Wu KL, Jiang GL, Qian H, Wang LJ, Yang HJ, Fu XL, et al. Three-
dimensional conformal radiotherapy for locoregionally recurrent lung carci-
noma after external beam irradiation: a prospective phase I-II clinical trial.
Int J Radiat Oncol Biol Phys (2003) 57(5):1345–50. doi:10.1016/S0360-3016(03)
00768-5
25. Tada T, Fukuda H, Matsui K, Hirashima T, Hosono M, Takada Y, et al. Non-
small-cell lung cancer: reirradiation for loco-regional relapse previously treated
with radiation therapy. Int J Clin Oncol (2005) 10(4):247–50. doi:10.1007/
s10147-005-0526-5
26. McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, et al. Definitive reirradi-
ation for locoregionally recurrent non-small cell lung cancer with proton beam
therapy or intensity modulated radiation therapy: predictors of high-grade
toxicity and survival outcomes. Int J RadiatOncol Biol Phys (2014) 90(4):819–27.
doi:10.1016/j.ijrobp.2014.07.030
27. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al.
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment
for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys (1999)
45(2):323–9. doi:10.1016/S0360-3016(99)00183-2
28. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, et al.
Radiation pneumonitis as a function of mean lung dose: an analysis of pooled
data of 540 patients. Int J Radiat Oncol Biol Phys (1998) 42(1):1–9. doi:10.1016/
S0360-3016(98)00196-5
29. Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB Jr, Ajani JA, et al.
Postoperative pulmonary complications after preoperative chemoradiation for
esophageal carcinoma: correlation with pulmonary dose-volume histogram
parameters. Int J Radiat Oncol Biol Phys (2003) 57(5):1317–22. doi:10.1016/
S0360-3016(03)01373-7
30. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of
treatment-related pneumonitis in advanced-stage non-small-cell lung cancer
patients treated with concurrent chemotherapy and intensity-modulated radio-
therapy. Int J Radiat Oncol Biol Phys (2007) 68(1):94–102. doi:10.1016/j.ijrobp.
2006.12.031
31. Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, et al. Dose-
response relationship for radiation-induced pneumonitis after pulmonary
stereotactic body radiotherapy. Radiother Oncol (2010) 97(1):65–70. doi:10.
1016/j.radonc.2010.04.027
32. Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, et al.
Dose – volumemetrics associated with radiation pneumonitis after stereotactic
body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2012)
83(4):e545–9. doi:10.1016/j.ijrobp.2012.01.018
33. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al.
Excessive toxicitywhen treating central tumors in a phase II study of stereotactic
body radiation therapy for medically inoperable early-stage lung cancer. J Clin
Oncol (2006) 24(30):4833–9. doi:10.1200/JCO.2006.07.5937
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Gill, Clump, Burton, Christie, Schuchert and Heron. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 1097
